{
    "clinical_study": {
        "@rank": "116125", 
        "arm_group": [
            {
                "arm_group_label": "Injectafer", 
                "arm_group_type": "Active Comparator", 
                "description": "2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg"
            }, 
            {
                "arm_group_label": "Ferrous Sulfate tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the treatment response of Injectafer vs.\n      oral iron to baseline hepcidin levels to determine if any of these select IBD patients may\n      demonstrate to be inappropriate for oral iron therapy."
        }, 
        "brief_title": "Treatment Response of Injectafer vs. Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD)", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases", 
                "Deficiency Diseases", 
                "Anemia, Iron-Deficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study is to evaluate the treatment response of Injectafer vs.\n      oral iron in patients with varying hepcidin levels correlating the treatment\n      response/hepcidin levels to more common laboratory parameters such as ferritin and CRP\n      (C-Reactive Protein) levels and possibly determine if any of these select IBD patients may\n      demonstrate to be inappropriate for oral iron therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent\n\n          -  Male or female subjects \u2265 18 years of age with clinical diagnosis of IDA secondary to\n             IBD\n\n          -  Screening Hemoglobin (Hb) \u2264 11g/dL\n\n          -  Screening Ferritin \u2264 100 ng/mL\n\n          -  Female subjects who are of childbearing age must have a negative pregnancy test at\n             screening and be practicing an acceptable method of birth control during the study\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity reaction to any component of IV Injectafer or oral iron\n\n          -  Requires dialysis for treatment of chronic kidney disease (CKD)\n\n          -  During the 30 day period prior to screening has been treated with IV iron\n\n          -  No evidence of iron deficiency\n\n          -  During the 30 day period prior to screening has been treated with a red blood cell\n             transfusion.\n\n          -  Any non-viral infection\n\n          -  Known positive hepatitis with evidence of active disease\n\n          -  Received an investigational drug within 30 days of screening\n\n          -  Active malignancy within 5 years. Basal or squamous cell skin cancer is not\n             exclusionary\n\n          -  Alcohol or drug abuse within the past 6 months\n\n          -  Hemochromatosis or other iron storage disorders\n\n          -  Pregnant\n\n          -  Any other laboratory abnormality, medical condition, or psychiatric disorders which\n             in the opinion of the Investigator would put the subject's disease management at risk\n             or may result in the subject being unable to comply with the study requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086968", 
            "org_study_id": "1VIT13035"
        }, 
        "intervention": [
            {
                "arm_group_label": "Injectafer", 
                "description": "2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg", 
                "intervention_name": "Injectafer", 
                "intervention_type": "Drug", 
                "other_name": "Ferric Carboxymaltose (FCM)"
            }, 
            {
                "arm_group_label": "Ferrous Sulfate tablets", 
                "description": "325mg (1 tablet) three times a day for 28 days", 
                "intervention_name": "Ferrous Sulfate tablets", 
                "intervention_type": "Drug", 
                "other_name": "Oral Iron tablets"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Iron", 
                "Ferric Compounds"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 12, 2014", 
        "location": {
            "contact": {
                "email": "mtokars@lpicrd.com", 
                "last_name": "Marc Tokars", 
                "phone": "610-650-4200", 
                "phone_ext": "805"
            }, 
            "contact_backup": {
                "email": "abutcher@lpicrd.com", 
                "last_name": "Angelia Butcher", 
                "phone": "610-650-4200", 
                "phone_ext": "811"
            }, 
            "facility": {
                "address": {
                    "city": "Norristown", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19403"
                }, 
                "name": "Luitpold Pharmaceuticals, Inc."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer vs. Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD)", 
        "overall_contact": {
            "email": "abutcher@lpicrd.com", 
            "last_name": "Angelia Butcher", 
            "phone": "610-650-4200", 
            "phone_ext": "811"
        }, 
        "overall_contact_backup": {
            "email": "mtokars@lpicrd.com", 
            "last_name": "Marc Tokars", 
            "phone": "610-650-4200", 
            "phone_ext": "805"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the correlation between screening hepcidin and change in hemoglobin from baseline to highest observed hemoglobin change.", 
            "measure": "Correlation between screening hepcidin and change in hemoglobin from baseline to highest observed hemoglobin change.", 
            "safety_issue": "No", 
            "time_frame": "anytime between baseline and end of study (day 28) or time of intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086968"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Luitpold Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Luitpold Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}